Malignant Pleural Mesothelioma

Quoted from http://www.jnccn.org/content/10/1/26.extract

Malignant Pleural Mesothelioma

NOTE:  Since this article has no abstract, we have provided an extract of the first 250 words of the full text.

Overview

Mesothelioma is a rare cancer that is estimated to occur in approximately 2500 people in the United States every year.1,2 These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type; mesothelioma can also occur in other sites (e.g., peritoneum, pericardium, tunica vaginalis testis). The disease is difficult to treat.

NCCN Clinical Practice Guidelines in Oncology for Malignant Pleural Mesothelioma

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. median overall survival is only approximately 1 year. MPM occurs mainly in older men (median age, 72 years) who have been exposed to asbestos, although it occurs decades after exposure (20-40 years later).3,4

The incidence of MPM is leveling off in the United States, because asbestos use has decreased since the 1970s; however, the United States still has more cases than anywhere else in the world.5,6 Although asbestos is no longer mined in the United States, it is still imported.6 The incidence of MPM is increasing in other countries, such as Russia, Western Europe, China, and India.1,5,7-11 Mortality rates from MPM are highest in the United Kingdom, Netherlands, and Australia, and are increasing in several other countries, such as Japan, Argentina, and Brazil.7

[Full Text of this Article]

Speak Your Mind

*

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Email@LambLawOffice.com
Disclaimer and Copyright